ArticleInternational journal of medical sciences2005
Advances in Molecular Diagnosis of HBV Infection and Drug Resistance.
Article in International journal of medical sciences, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 65 citations in OpenAlex.
- Quantification of Hepatitis B Virus DNA: Validation of a qPCR Approach to detect Pregnant Women at High Risk to Transmit the Virus in Mali.Revue malienne d'infectiologie et de microbiologie · 2024Article
- Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants.Virology journal · 2013Article
- Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.Hepatology international · 2013Article
- Antiviral therapies: focus on hepatitis B reverse transcriptase.The international journal of biochemistry & cell biology · 2012Review
- Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.Antimicrobial agents and chemotherapy · 2010Article
- Viral resistance in hepatitis B: prevalence and management.Current gastroenterology reports · 2010Article
- Molecular diagnosis of entecavir resistance.Hepatitis monthly · 2010Article
- Genotype A2/adw2 Strain of Hepatitis B Virus in Turkey.Hepatitis monthly · 2010Article
- Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.Journal of virology · 2009Article
- Current status of antiviral therapy for hepatitis B.Therapeutic advances in gastroenterology · 2008Article
- Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B.World journal of gastroenterology · 2008Article
- Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.Journal of cancer research and clinical oncology · 2007Article
- Review.Gastroenterology & hepatology · 2007Article
- Molecular analysis of hepatitis B virus "a" determinant in asymptomatic and symptomatic Mexican carriers.Virology journal · 2007Article
- Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B.World journal of gastroenterology · 2006Article
- Correlation between HBsAg quantitation and HBV DNA in HBeAg-negative HBV/D patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serological markers are key elements in diagnosing acute hepatitis B virus (HBV) infection and determining its possible evolution towards chronicity. Once treatment of chronic HBV is initiated with approved anti-hepadnaviral agents, such as lamivudine, interferon-alpha, or adefovir dipivoxil, the measurement of HBV DNA in serum can not only help monitor treatment efficacy but also indicates breakthrough infection should drug resistance emerge. Advances in the molecular diagnosis of drug resistance using highly sensitive methodologies such as DNA hybridization assays can further pinpoint the type of mutation responsible and, more importantly, detect upcoming viral resistance at an early stage when the variant represents only a minor fraction of the total viral population. Such new tools are especially relevant for patients at high risk for disease progression or acute exacerbation. Recent diagnostic developments including HBV genotyping and precore/core promoter assays that could well play important future roles in HBV patient management are also reviewed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.